Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment, and you are unlikely to be protected if something goes wrong.
Take two mins to learn more
Differentiated technology: Direct-from-blood cfDNA extraction delivering higher yields, faster processing, and simplified automation-ready workflows.
Strong market tailwinds: Rapid growth in liquid biopsy and precision diagnostics is increasing demand for improved pre-analytical solutions.
Clear competitive advantage: Demonstrated performance superiority versus gold-standard extraction methods with improved consistency and workflow efficiency.
Commercial potential: Early engagement with diagnostics OEMs, research labs, and industry partners supporting the scalable adoption and strategic exit pathways.

